Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
Asians
Heart failure
Sacubitril/valsartan
Journal
Korean circulation journal
ISSN: 1738-5520
Titre abrégé: Korean Circ J
Pays: Korea (South)
ID NLM: 101247141
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
06
05
2019
accepted:
19
05
2019
entrez:
8
6
2019
pubmed:
7
6
2019
medline:
7
6
2019
Statut:
ppublish
Résumé
The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system blocker (and other standard therapy) reduced morbidity and mortality in ambulatory patients with chronic HF with reduced ejection fraction (HFrEF). In PARADIGM-HF, valsartan combined with sacubitril (a so-called ARNI) was superior to the current gold standard of an ACEI, specifically enalapril, reducing the risk of the primary composite outcome of cardiovascular (CV) death or first HF hospitalization by 20% and all-cause death by 16%. Following the results of PARADIGM-HF, sacubitril/valsartan was approved by American and European regulatory authorities for the treatment of HFrEF. The burden of HF in Asia is substantial, both due to the huge population of the region and as a result of increasing CV risk factors and disease. Both the prevalence and mortality associated with HF are high in Asia. In the following review, we discuss the development of sacubitril/valsartan, the prototype ARNI, and the available evidence for its efficacy and safety in Asian patients with HFrEF.
Identifiants
pubmed: 31172710
pii: 49.469
doi: 10.4070/kcj.2019.0136
pmc: PMC6554586
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
469-484Subventions
Organisme : British Heart Foundation
ID : PG/17/23/32850
Pays : United Kingdom
Informations de copyright
Copyright © 2019. The Korean Society of Cardiology.
Déclaration de conflit d'intérêts
Dr. Docherty is conducting an investigator originated study funded by the British Heart Foundation (project grant No. PG/17/23/32850) using sacubitril/valsartan supplied by Novatis. The other authors have no financial conflicts of interest.
Références
Am Heart J. 1999 Dec;138(6 Pt 1):1149-57
pubmed: 10577447
Lancet. 2000 Aug 19;356(9230):615-20
pubmed: 10968433
N Engl J Med. 2001 Dec 6;345(23):1667-75
pubmed: 11759645
Circulation. 2002 Aug 20;106(8):920-6
pubmed: 12186794
J Hypertens. 1992 Jul;10(7):607-13
pubmed: 1321186
N Engl J Med. 1992 Sep 3;327(10):685-91
pubmed: 1463530
Am J Hypertens. 2004 Feb;17(2):103-11
pubmed: 14751650
Eur J Heart Fail. 2004 Jun;6(4):467-75
pubmed: 15182773
Circulation. 2005 Oct 18;112(16):2426-35
pubmed: 16143696
Br J Pharmacol. 2008 Mar;153(5):947-55
pubmed: 18084312
J Am Coll Cardiol. 2007 Dec 18;50(25):2357-68
pubmed: 18154959
Clin Sci (Lond). 1991 Mar;80(3):265-9
pubmed: 1850687
Lancet. 1990 Jan 13;335(8681):118-9
pubmed: 1967410
J Clin Pharmacol. 2010 Apr;50(4):401-14
pubmed: 19934029
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 1991 Aug 1;325(5):303-10
pubmed: 2057035
FEBS J. 2011 Jun;278(11):1808-17
pubmed: 21375692
N Engl J Med. 2011 Jul 7;365(1):32-43
pubmed: 21732835
Int J Neurosci. 2013 Mar;123(3):143-54
pubmed: 23110469
Cardiovasc Ther. 2014 Feb;32(1):13-8
pubmed: 24138103
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7580-4
pubmed: 2529543
Lancet. 1989 Sep 9;2(8663):591-3
pubmed: 2570286
Eur Heart J. 2015 Aug 7;36(30):1990-7
pubmed: 26022006
Eur Heart J. 2015 Oct 7;36(38):2576-84
pubmed: 26231885
J Am Coll Cardiol. 2015 Dec 8;66(22):2536-49
pubmed: 26653629
N Engl J Med. 2016 Apr 21;374(16):1521-32
pubmed: 27043774
Eur J Heart Fail. 2016 Sep;18(9):1193-202
pubmed: 27170530
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
JACC Heart Fail. 2016 Jun;4(6):419-27
pubmed: 27256745
Eur Heart J. 2016 Nov 01;37(41):3167-3174
pubmed: 27354044
Eur J Heart Fail. 2016 Oct;18(10):1238-1243
pubmed: 27364182
Chembiochem. 2016 Aug 17;17(16):1495-8
pubmed: 27377680
J Am Coll Cardiol. 2016 Aug 9;68(6):639-653
pubmed: 27491909
Eur Heart J. 2016 Nov 01;37(41):3141-3153
pubmed: 27502121
Int J Cardiol. 2016 Nov 15;223:163-167
pubmed: 27541646
Circ Heart Fail. 2016 Sep;9(9):
pubmed: 27618854
Hosp Pharm. 2015 Nov;50(11):1025-36
pubmed: 27621510
Eur J Heart Fail. 2017 Jan;19(1):129-137
pubmed: 27868321
J Cardiol. 2017 Sep;70(3):225-231
pubmed: 28024961
N Engl J Med. 2017 May 18;376(20):1956-1964
pubmed: 28402745
Clin Pharmacokinet. 2017 Dec;56(12):1461-1478
pubmed: 28417439
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
Lancet Glob Health. 2017 Jul;5(7):e665-e672
pubmed: 28476564
JACC Heart Fail. 2017 Jul;5(7):471-482
pubmed: 28662936
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
Korean Circ J. 2017 Sep;47(5):555-643
pubmed: 28955381
Circ Heart Fail. 2018 Jul;11(7):e004962
pubmed: 29980595
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018
pubmed: 30103979
Indian Heart J. 2018 Jul;70 Suppl 1:S1-S72
pubmed: 30122238
N Engl J Med. 2019 Feb 7;380(6):539-548
pubmed: 30415601
Eur J Heart Fail. 2019 May;21(5):577-587
pubmed: 30536678
Biochem J. 1974 Mar;137(3):477-88
pubmed: 4423492
Nature. 1980 Nov 20;288(5788):286-8
pubmed: 7001254
Life Sci. 1981 Jan 5;28(1):89-94
pubmed: 7219045
Br J Clin Pharmacol. 1995 Aug;40(2):141-4
pubmed: 8562296
J Med Chem. 1997 May 23;40(11):1570-7
pubmed: 9171867
Circulation. 1998 Jun 16;97(23):2323-30
pubmed: 9639376